NL-OMON26600RecruitingNot Applicable
An Open-label Phase I/IIa Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or recurrent malignant glioma.
to-BBB Technologies B.V.to-BBB technologies BVNiels Bohrweg 11, 2333 CA LeidenBio Partner Center IIThe NetherlandsPhone: +31 (0) 71 3322256Fax: +31 (0) 84 8313409Email: gladdines@tobbb.com0 sites40 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 40
Study Overview
Brief Summary
/A
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1. Age at least 18 years;
- •2. Measurable or evaluable brain disease;
Exclusion Criteria
- •Prior Treatment:
- •1. Less than 4 weeks since the last treatment of chemotherapy, biological therapy, immunotherapy and systemic radiotherapy (except palliative radiation delivered to <20% of bone marrow), less than 8 weeks for cranial radiotherapy, and less than 6 weeks for nitrosoureas and mitomycin C;
Investigators
Similar Trials
Withdrawn
Phase 1
Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS IIMucopolysaccharidosis IINCT05238324Homology Medicines, Inc
Active, not recruiting
Phase 1
A Study to Test Trametinib and dabrafenib in Children and Adolescents Subjects with CancerChildren and Adolescents with Cancers Harboring V600 mutationsMedDRA version: 17.1Level: PTClassification code 10029260Term: NeuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003596-35-FRGlaxoSmithKline Research & Development Ltd94
Active, not recruiting
Phase 1
A Study to Test Trametinib and dabrafenib in Children and Adolescents Subjects with CancerChildren and Adolescents with Cancers Harboring V600 mutationsMedDRA version: 20.0Level: PTClassification code 10029260Term: NeuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003596-35-GBovartis Pharma Services AG145
Active, not recruiting
Phase 1
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects with Relapsed or Refractory LeukemiasEUCTR2009-017376-25-BEGlaxoSmithKline Research & Development Ltd135
Active, not recruiting
Not Applicable
A phase 1/II study to investigate how the drug GSK1120212 behaves, its safety and effectiveness in subjects with cancer of blood cellsRelapsed or refractory leukemiasMedDRA version: 14.1Level: PTClassification code 10000880Term: Acute myeloid leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-017376-25-DEGlaxoSmithKline Research & Development Ltd135